Javascript must be enabled to continue!
Evaluation of Anticoagulation Outcome among Patients Taking Warfarin: A Single-Center Experience, Northwest Ethiopia
View through CrossRef
Abstract
BackgroundWarfarin is a widely used oral anticoagulant in clinical practice. It is used to prevent arterial emboli in patients with atrial fibrillation, or prevent and treat venous thromboembolism. The efficacy and safety of warfarin depends on maintaining the INR within the therapeutic range. The proportion of time spent in the therapeutic INR range (TTR) is used to evaluate quality of anticoagulation control.MethodsA hospital-based cross sectional study was conducted between November 1, 2019 and October 31, 2020 at Cardiac and Hematology Clinic, University of Gondar hospital. A consecutive sampling method was used to recruit 338 study subjects. Proportion of time spent in the therapeutic range (TTR) was calculated using the Rosendaal’s linear interpolation method. TTR ≥65% was described as ‘optimal’ International Normalized Ratio (INR) control. The Data were entered into EPI Info version 4.4.1 and transported to SPSS version 20 for analysis. Logistic regression analysis was used to identify associated factors with optimal anticoagulation outcome (TTR ≥65%). P-values <0.05 were used to declare significant association.ResultA total of 338 study subjects were included in the study. The mean age of patients was 49 years. The majority of study participants attended formal education (79%) and were urban dwellers (57%). Atrial fibrillation was the commonest indication for warfarin therapy. One-third (33%) of study subjects achieved the desired INRs (INR=2.0-3.0), while about one-tenth (13%) of patients attained optimal INR control (TTR≥65%). There were no significant association of socio-demographic characteristics including age, gender, educational level and monthly income with optimal INR control (TTR ≥65%). Likewise, clinical characteristics including dose of warfarin, warfarin adherence, frequency of INR determination, other concomitant drug intake, co-existing comorbidities, consumption of green leafy vegetables and alcohol intake didn’t show significant association with optimal INR control (TTR≥65%).ConclusionInstitution-based validated protocol might be required to overcome the poor TTR level. ‘Anticoagulation (INR) clinic’ would be required to ‘scale-up’ INR control.
Title: Evaluation of Anticoagulation Outcome among Patients Taking Warfarin: A Single-Center Experience, Northwest Ethiopia
Description:
Abstract
BackgroundWarfarin is a widely used oral anticoagulant in clinical practice.
It is used to prevent arterial emboli in patients with atrial fibrillation, or prevent and treat venous thromboembolism.
The efficacy and safety of warfarin depends on maintaining the INR within the therapeutic range.
The proportion of time spent in the therapeutic INR range (TTR) is used to evaluate quality of anticoagulation control.
MethodsA hospital-based cross sectional study was conducted between November 1, 2019 and October 31, 2020 at Cardiac and Hematology Clinic, University of Gondar hospital.
A consecutive sampling method was used to recruit 338 study subjects.
Proportion of time spent in the therapeutic range (TTR) was calculated using the Rosendaal’s linear interpolation method.
TTR ≥65% was described as ‘optimal’ International Normalized Ratio (INR) control.
The Data were entered into EPI Info version 4.
4.
1 and transported to SPSS version 20 for analysis.
Logistic regression analysis was used to identify associated factors with optimal anticoagulation outcome (TTR ≥65%).
P-values <0.
05 were used to declare significant association.
ResultA total of 338 study subjects were included in the study.
The mean age of patients was 49 years.
The majority of study participants attended formal education (79%) and were urban dwellers (57%).
Atrial fibrillation was the commonest indication for warfarin therapy.
One-third (33%) of study subjects achieved the desired INRs (INR=2.
0-3.
0), while about one-tenth (13%) of patients attained optimal INR control (TTR≥65%).
There were no significant association of socio-demographic characteristics including age, gender, educational level and monthly income with optimal INR control (TTR ≥65%).
Likewise, clinical characteristics including dose of warfarin, warfarin adherence, frequency of INR determination, other concomitant drug intake, co-existing comorbidities, consumption of green leafy vegetables and alcohol intake didn’t show significant association with optimal INR control (TTR≥65%).
ConclusionInstitution-based validated protocol might be required to overcome the poor TTR level.
‘Anticoagulation (INR) clinic’ would be required to ‘scale-up’ INR control.
Related Results
Establishment of pharmacogenomic algorithm for predicting stable warfarin dose in Chinese patients
Establishment of pharmacogenomic algorithm for predicting stable warfarin dose in Chinese patients
Background
Genetic variants of cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) are known to influence warfarin dose, but the effect of other...
Abstract 448: Assessment of Drug Interaction Potential Between LCZ696 and Warfarin
Abstract 448: Assessment of Drug Interaction Potential Between LCZ696 and Warfarin
Objective:
LCZ696 is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) being developed for the treatment of cardiovascular diseases including hypertensi...
Outcomes with prophylactic anticoagulation in hemolytic anemias: A systematic review
Outcomes with prophylactic anticoagulation in hemolytic anemias: A systematic review
Abstract
Introduction:
Venous thromboembolism (VTE) is one of the most common causes of mortality in...
Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin
Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin
INTRODUCTION: Recent large randomized controlled trials have shown that novel oral anticoagulants (NOACs) are at least as effective as warfarin for risk reduction of stroke or syst...
Therapeutic versus Prophylactic Anticoagulation for Patients Admitted to Hospital with COVID-19 and Elevated D-dimer Concentration (ACTION): An Open-Label, Multicentre, Randomised, Controlled Trial
Therapeutic versus Prophylactic Anticoagulation for Patients Admitted to Hospital with COVID-19 and Elevated D-dimer Concentration (ACTION): An Open-Label, Multicentre, Randomised, Controlled Trial
Background. COVID-19 is associated with a prothrombotic state leading to adverse clinical outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised w...
Diplomatic Claims (Eritrea v. Ethiopia), Eritrea ' s Claim 20/Ethiopia ' s Claim 8, Partial Awards; Economic Loss Throughout Ethiopia (Ethiopia v. Eritrea), Ethiopia ' s Claim 7, Partial Award; Jus ad Bellum (Ethiopia v. Eritrea), Ethiopia ' s Claims 1-8,
Diplomatic Claims (Eritrea v. Ethiopia), Eritrea ' s Claim 20/Ethiopia ' s Claim 8, Partial Awards; Economic Loss Throughout Ethiopia (Ethiopia v. Eritrea), Ethiopia ' s Claim 7, Partial Award; Jus ad Bellum (Ethiopia v. Eritrea), Ethiopia ' s Claims 1-8,
Diplomatic Claims (Eritrea v. Ethiopia), Eritrea's Claim 20/Ethiopia's Claim 8, Partial Awards. At <http://www.pca-cpa.org>.Eritrea Ethiopia Claims Commission, December 19, 2...
Warfarin and GLP-1 Receptor Agonist Interaction Effects on Time in Therapeutic Range
Warfarin and GLP-1 Receptor Agonist Interaction Effects on Time in Therapeutic Range
Background
Warfarin is a commonly prescribed anticoagulant with many dietary and medication interactions. Warfarin's therapeutic efficacy is monitored using the I...
Building a predictive model for warfarin dosing via machine learning
Building a predictive model for warfarin dosing via machine learning
Abstract
Background
Warfarin titration via International Normalised Ratio (INR) monitoring can be a challenge for patients on lo...

